Non-small Cell Lung Cancer

Electromagnetic Navigation Bronchoscopy – pro

ENB (Electromagnetic Navigation Bronchoscopy) or EMN bronchoscopy is a type of bronchoscopy that uses electromagnetic guidance to project catheters into and through bronchial passages. Using a virtual, three-dimensional (3D) bronchial map from a recent CT scan and disposable catheters, it makes it possible to navigate to a desired location within the lung  and to look at it or biopsy it, stage lymphatic nodes or to insert markers to guide future

Read more
Irinotecan for brain metastases of breast and lung cancer -pro

Because irinotecan penetrates the brain-blood barrier and has an effect in primary brain cancer, there is some interest in using it for brain metastasis, especially for lung cancer and breast cancer. Most studies of irinotecan had been for brain mets of small(SCLC) and non-small cell lung cancer(NSMCLC) and not breast cancer and have had mixed results. One study reported complete responses with irinotecan-based chemotherapy for brain metastases in

Read more
Adjuvant chemo for NSCLC – pro

Non-small cell lung cancer is a frequent type of cancer, with approximately 1.2 million cases per year expected worldwide. A total of 20-30% of patients with early stage non-small cell lung cancer are amenable to radical surgery, although only 40-50% of these patients are cured. An improvement in survival has never been demonstrated for postoperative radiotherapy. However, a major step forward is several recent large randomized studies that have

Read more
Delay in diagnosis of lung cancer – pro

Lung cancer is symptomatic in over 90% of patients. However, studies find that delays between reporting of symptoms and diagnosis are universal. In a recent Swedish study, 134 lung cancer patients were investigated prospectively. The median delay for the patients, i.e. from the first symptom(s) until the family doctor was contacted, was 21 days. From the first contact with the doctor until referral to the specialist the median time was 33 days. From

Read more
PET for restaging NSCLC – pro

PET is clearly accepted for lung cancer staging while deciding on potentially operative therapy. For restaging, Medicare accepts it as follows: PET is covered for restaging: (1) after completion of treatment for the purpose of detecting residual disease, (2) for detecting suspected recurrence or metastasis, (3) to determine the extent of a known recurrence, or (4) if it could potentially replace one or more conventional imaging studies when it is

Read more
Irinotecan/Carboplatin/ pacalitaxel in NSCLC – pro

Lung cancer is the leading cause of cancer death in the United States and in the world. In the United States, lung cancer ranks first in cancer deaths for both men and women. The 5-year survival rate is only 15%, but this has improved considerably from the 5% rate in the early 1960s. For many years, the standard therapy for patients with advanced, stage IIIB and IV non small-cell lung cancer (NSCLC) was best supportive care, which consisted of palliative

Read more
Chemo in poor performance lung cancer – pro

Poor performance status patients with advanced non-small cell lung cancer (NSCLC) have frequently been excluded from clinical trials due to the perception that they would have excessive treatment-related toxicity and a limited life expectancy. A recent retrospective review of two multicenter trials of patients who were treated with platinum-based chemotherapy for advanced NSCLC showed that patients with poor performance status treated with platinum

Read more
Radiofrequency ablation for lung mets – pro

Lay Summary: Radiofrequency Ablation of lung mets requires more study before it can considered standard of care. The lung is the most common site for primary cancer worldwide as well as being a common site of metastases for various malignancies. Percutaneous radiofrequency ablation (RFA) is rapidly evolving as a new minimally invasive tool for the treatment of pulmonary tumors(1.2). Although such early experience appears promising, many questions

Read more
ALIMTA for squamous lung cancer – pro

On September 26, 2008, the U. S. Food and Drug Administration (FDA) approved pemetrexed injection (Alimta Injection, Eli Lilly and Company) for use in combination with cisplatin therapy for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Pemetrexed is not indicated for treatment of patients with squamous cell lung carcinoma. A multicenter, randomized, open-label study in 1725

Read more
Sprycel for lung cancer – pro

Sprycel is approved for 2nd line treatment of CML. Sprycel has been developed for the treatment of patients with BCR-ABL-positive CML and acute lymphoblastic leukemia (ALL); for the treatment of patients who fail Gleevec. Sprycel is approved by the U.S. Food and Drug Administration for treatment of patients who fail or are intolerant to Gleeevec. There rare several trial of this agent for lung cancer, for example:Dasatinib in Advanced Non-small Cell

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/blog_category.php on line 39